Munich

IOWN Global Forum Hosts Successful Member Meeting in Munich, Accelerating Innovation for a Smarter, Connected World

Retrieved on: 
Dienstag, September 19, 2023
Networks, Internet, Mobile, Wireless, Technology, Telecommunications, Composable disaggregated infrastructure, Communication, Shiga University, Senior, Sony, Synthetic media, Chairperson, NTT Comware, NTT, Chair, APN, KDDI, Research, Organization, SR, Report, Intel, Quality of service, Material, Juniper Networks, Silicon photonics, Accenture, POC, Exhibition, Interop, Push technology, AMD, Nagoya University, TSC, Generative, Forum, Taisei Corporation, Munich, Speech, Viavi Solutions, DCI, Connections, Technological evolution, Movement, Kyocera, Silicon, Mobile phone, Medical device, Management

The Innovative Optical and Wireless Network Global Forum (IOWN Global Forum) which seeks to create a smarter, more sustainable and connected world, recently hosted its first member meeting in Europe, welcoming nearly 200 registrants from nearly 50 different organizations.

Key Points: 
  • The Innovative Optical and Wireless Network Global Forum (IOWN Global Forum) which seeks to create a smarter, more sustainable and connected world, recently hosted its first member meeting in Europe, welcoming nearly 200 registrants from nearly 50 different organizations.
  • As a contribution-led organization, the direction of the IOWN Global Forum is based on a highly collaborative process.
  • To further guide the work of the IOWN Global Forum, the Technical Steering Committee has publicly released the " IOWN Global Forum: Key Values and Technology Evolution Roadmap " reference document.
  • In his welcome, Dr. Katsuhiko Kawazoe, President and Chairperson of IOWN Global Forum, shared his observations on the combination of Generative AI and IOWN technologies.

EQS-News: Formycon reports results for the first quarter 2023

Retrieved on: 
Donnerstag, Juni 1, 2023
Partnership, International, KG, MedImmune, Inc. v. Genentech, Inc., FYB, EBIT, Esselte Leitz GmbH & Co KG, Gesellschaft mit beschränkter Haftung, EBITDA, Euro, Physician, ISIN, CFO, Munich, Security (finance), Tourism

Formycon Group’s revenues increased to a total of Euro 21.5. million in the first quarter of 2023 (Q1/2022: Euro 8.1 million).

Key Points: 
  • Formycon Group’s revenues increased to a total of Euro 21.5. million in the first quarter of 2023 (Q1/2022: Euro 8.1 million).
  • A significant part of revenues resulted from a first milestone payment as part of the commercialization partnership from project FYB202 signed in Q1/2023.
  • „In terms of key figures, the first quarter of 2023 was characterized by various positive special effects.
  • We continue to confirm our guidance for 2023", commented Enno Spillner, CFO of Formycon AG.

"Atlas of Impunity" documents rise of unaccountable power in new and comprehensive global index

Retrieved on: 
Freitag, Februar 17, 2023
Woman, Government, Darkness, Authoritarianism, Eurasia Group, Developed country, Chicago, Violence, System, Munich, Pathway to Adventure Council, Open Society Foundations, Pernicious, Colonialism, Global Affairs Canada, Statistics, Democracy, Interview, Policy, INDEX, Politics, Instinct, Crime, Theocracy, 52nd Munich Security Conference, Exercise, FOR, Impunity, Environment, Conference, Corrosion engineering, 101st Airborne Division, Film industry, Drug, Renewable energy

MUNICH, Feb. 17, 2023 /PRNewswire-PRWeb/ -- The Eurasia Group and the Chicago Council on Global Affairs today publish the world's first Atlas of Impunity at the Munich Security Conference, a comprehensive index which tracks the abuse of power across five key societal dimensions – unaccountable governance, abuse of human rights, conflict, economic exploitation. and environmental degradation.

Key Points: 
  • The inaugural Atlas defines impunity as the exercise of power without checks and balances.
  • The Atlas is designed to spark vigorous debate on the rise of unaccountable power worldwide.
  • This lens also highlights the ways in which impunity undermines democratic societies and accountability manifests in nondemocratic systems.
  • The lens of impunity and accountability captures the multidimensional nature of global challenges and the shirking of public responsibility.

DGAP-News: Rational AG: strongest half year in terms of sales revenues – nevertheless cautious

Retrieved on: 
Mittwoch, August 3, 2022
Food, CFO, Environment, EBIT, MDAX, CEO, Social responsibility, Rationality, Central processing unit, Wirtschaftswoche, Leadership, Technology, Munich, Pressure, Many, Tax, Growth, IG Metall, Rational AG, Chemical, Video game, State

As in the first quarter, Rational was again affected by the low availability of processors (CPUs) in the second quarter of 2022.

Key Points: 
  • As in the first quarter, Rational was again affected by the low availability of processors (CPUs) in the second quarter of 2022.
  • Sales revenues by product group: iVario defies supply difficulties and grows by 50 percent
    Both product groups of the Rational Group contributed to growth.
  • In the iCombi product group, sales revenues were up 17 percent year on year in the first half of 2022, at 395.1 million euros (2021: 337.6 million euros).
  • In the iVario product group, sales revenues rose by 50 percent to a new record level of 62.6 million euros (2021: 41.7 million euros).

Prime Minister participates in successful visit to Germany

Retrieved on: 
Mittwoch, März 9, 2022
Development, Government, Industry, Chairperson, FDI, Mineral, Organization, Economy, Partnership, Empowerment, Democracy, Statistics, G7 Rapid Response Mechanism, Hydrogen, World, Conference, G20, Adoption, Global Carbon Council, World Trade Organization, Aggression, The Holocaust, CETA, Leadership, Climate change, Courage, Science, Grunewald, Statistics Canada, Munich, Munich Security Conference, Authoritarianism, RRM, NATO, Freedom, Jews, Organisation for Economic Co-operation and Development controversy, Renewable energy, Online gambling, Atlantic Ocean, G7, EU

BERLIN, March 9, 2022 /CNW/ -The Prime Minister, Justin Trudeau, today had a successful bilateral visit to Germany.

Key Points: 
  • BERLIN, March 9, 2022 /CNW/ -The Prime Minister, Justin Trudeau, today had a successful bilateral visit to Germany.
  • The Prime Minister today also announced that Canada would provide an additional $50 million in lethal and non-lethal military equipment to Ukraine.
  • In Germany, the Prime Minister delivered a keynote address on international peace, security and transatlantic cooperation at the Allianz Forum, hosted by Atlantik-Brcke and Munich Security Conference.
  • In his remarks, the Prime Minister emphasized that Canada will always stand up for democratic values and against authoritarianism.

HMNC Brain Health to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference

Retrieved on: 
Mittwoch, Dezember 1, 2021
Conference, MDD, Brain, Mental, Lists of diseases, TRD, GLOBE, Medical device

A webcast of the presentation will be available on the HMNC Brain Health Website for 90 days through the above webcast link.

Key Points: 
  • A webcast of the presentation will be available on the HMNC Brain Health Website for 90 days through the above webcast link.
  • HMNC Brain Healths management team will also participate in virtual one-on-one meetings over the duration of the conference.
  • HMNC Brain Health (HMNC Holding GmbH) is a biotech company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission.
  • HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices.

HMNC Brain Health to Participate in Microdose’s Wonderland: Miami Conference on November 8-9, 2021

Retrieved on: 
Dienstag, November 2, 2021
Adrienne Arsht Center for the Performing Arts, TRD, Conference, MDD, Brain, GLOBE, Performing arts, Lists of diseases, Medical device

HMNC Brain Healths management team will participate in virtual one-on-one meetings during the conference.

Key Points: 
  • HMNC Brain Healths management team will participate in virtual one-on-one meetings during the conference.
  • HMNC Brain Health (HMNC Holding GmbH) is a biotech company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission.
  • HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices.
  • The company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

HMNC Brain Health Appoints Head of Regulatory Affairs

Retrieved on: 
Montag, November 1, 2021
Head, University, TRD, Copenhagen, Mental health, Novo, Regulatory affairs, University of Copenhagen Faculty of Health and Medical Sciences, MDD, Novo Nordisk, GLOBE, Lists of diseases, Medical device

MUNICH, Nov. 01, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health ("HMNC" or the "company"), a clinical-stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, today announced the appointment of Dr. Katarina Jelic Maiboe as Head of Regulatory Affairs, effective November 1, 2021.

Key Points: 
  • MUNICH, Nov. 01, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health ("HMNC" or the "company"), a clinical-stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, today announced the appointment of Dr. Katarina Jelic Maiboe as Head of Regulatory Affairs, effective November 1, 2021.
  • "I am excited for the unique opportunity to join the HMNC Brain Health team and lead the regulatory process to further develop personalized therapies to treat people with mental health disorders and reduce the immense individual burden," said Dr. Maiboe.
  • HMNC Brain Health (HMNC Holding GmbH) is a biotech company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission.
  • HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices.

HMNC Brain Health Initiates Pioneering Precision Therapy Program in Mental Health

Retrieved on: 
Donnerstag, September 16, 2021
Program, ICON, Government, Biotechnology, Mental health, Lists of diseases, Patient, Anxiety, Phase, II, Physician, TRD, MDD, HPA, Brain, GLOBE, Psychiatry, Population, Medical device, Pharmaceutical industry

This is the first time ever that large-scale precision therapy studies are being conducted in the area of mental health.

Key Points: 
  • This is the first time ever that large-scale precision therapy studies are being conducted in the area of mental health.
  • The ability to apply this combined concept in depression therapy has the potential to be a significant breakthrough in the treatment of mental health disorders, said Dr. Hans Eriksson, Chief Clinical Development Officer of HMNC Brain Health.
  • HMNC Brain Health (HMNC Holding GmbH) is a clinical stage biopharma company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission.
  • HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices.

HMNC Brain Health to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Dienstag, September 7, 2021

In addition, HMNC Brain Healths management team will participate in virtual one-on-one meetings throughout the day.

Key Points: 
  • In addition, HMNC Brain Healths management team will participate in virtual one-on-one meetings throughout the day.
  • A webcast of the presentation will be available on the HMNC Brain Health Website for 90 days through the above webcast link.
  • HMNC Brain Health (HMNC Holding GmbH) is a biotech company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission.
  • HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices.